This podcast was initiated and funded by Bayer Australia Ltd.

The introduction of second-generation androgen-receptor inhibitors has altered the treatment paradigm for non-metastatic castrate-resistant prostate cancer (nmCRPC). In this podcast the limbic speaks to Doctor Neal Shore from the Carolina Urologic Research Centre in the United States and local oncologist Doctor Laurence Krieger from the Northern Cancer Institute in Sydney about how they approach patient-physician shared decision making when deciding on the best approach to treatment. Doctor Shore and Doctor Krieger also give their thoughts on value-based healthcare and future directions in treatment.